Lineage Cell Therapeutics (LCTX) vs Q32 Bio (QTTB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Q32 Bio (QTTB) has outperformed Lineage Cell Therapeutics (LCTX) over the past year, gaining 170.6% versus a loss of 40.5%. Over five years, LCTX leads with a -56.2% price change compared with -92.8% for QTTB. Lineage Cell Therapeutics is the larger company by market cap ($260.5 million vs $240.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LCTX | QTTB |
|---|---|---|
| Share price | $1.03 | $8.09 |
| Market cap | $260.49M | $240.83M |
| 1-day change | +8.70% | +1.25% |
| YTD return | -38.32% | +143.67% |
| 1-year return | -40.46% | +170.57% |
| 5-year return | -56.17% | -92.75% |
| P/E ratio (TTM) | — | 2.57 |
| EPS (TTM) | $-0.17 | $3.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.09 | $23.57 |
| 52-week low | $0.88 | $1.91 |
| Distance from 52-week high | -50.72% | -65.68% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +433.98% | +389.49% |
| Average volume | 1.15M | 1.38M |
| Shares outstanding | 252.91M | 29.77M |
| Employees | 72 | 22 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- QTTB has outperformed LCTX by 211.0 percentage points over the past year.
About Lineage Cell Therapeutics
LCTX stock →Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 72 employees
About Q32 Bio
QTTB stock →Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
LCTX vs QTTB FAQ
Which is bigger, Lineage Cell Therapeutics or Q32 Bio?
Lineage Cell Therapeutics (LCTX) is larger, with a market capitalization of $260.49M compared with $240.83M for Q32 Bio (QTTB).
Which stock has performed better over the past year, LCTX or QTTB?
QTTB returned +170.57% over the past 12 months, compared with -40.46% for LCTX (price return, excluding dividends). Past performance does not predict future results.
Are Lineage Cell Therapeutics and Q32 Bio in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Lineage Cell Therapeutics and Biotechnology: Pharmaceutical Preparations for Q32 Bio.